Biogen’s Aducanumab: One Positive Phase III Trial Is Good Enough For Demonstrating Efficacy, US FDA Says

 
• By Sue Sutter
  
New life idea concept with seedling growing sprout (tree)
US FDA believes the Phase III EMERGE trial can stand on its own as pivotal efficacy evidence for aducanumab. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers